Stifel analyst Rick Wise raised the firm’s price target on Boston Scientific (BSX) to $115 from $100 and keeps a Buy rating on the shares following what the firm calls “an excellent fourth quarter result.” The company’s positive performance appears primed to continue in 2025, contends the analyst, who expects improvement from Silk Road and Axonics as the company integrates both businesses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $120 from $112 at Baird
- Boston Scientific price target raised to $117 from $101 at Canaccord
- Boston Scientific price target raised to $122 from $107 at Citi
- Boston Scientific Reports Strong 2024 Financial Growth
- Boston Scientific Shines with Strong Earnings Performance